⌕
Vertex Pharmaceuticals · VRTX · Nasdaq
Tenet 55 · Mixed
Compare
$534.20−0.67%At closeTenet 55 · Mixed
$534.20−3.59 (−0.67%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
$530.05−4.15 (−0.78%)
After hours: Nov 17, 2026, 7:59 PM ET

Vertex Pharmaceuticals (VRTX) Institutional Ownership

13F filers reported holding 12.6% of Vertex Pharmaceuticals (VRTX) shares as of Sep 30, 2026, across 1,069 filers.

Sources Ownership filingsQuarter ended How we compute thisNot investment advice
Held by 13F filers
12.6%
Sep 30, 2026
13F filers
1,069
quarter ended Sep 30, 2026
13F value
$16.7B
31.9M shares
Quarter's fund flow
Mild accumulation
94 new · 47 closed

Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.

13F fund flowQuarter ended Sep 30, 2026: more funds added or entered than trimmed or exited, mild accumulation (94 new · 462 increased · 332 reduced · 47 closed · 134 unchanged or with no prior quarter on file). Flows at this scale move slowly; treat as context. These positions are 49 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
Basis: shares reported by 1,069 13F filers for Sep 30, 2026, over shares outstanding implied from the current quote, measured 49 days apart. It measures the ownership we have filings for, not total institutional ownership, and it moves with the share count between filings.
routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
DateNameRoleTypeSharesPriceSEC filing
Oct 20, 2026Brennan Daniel J.directorAcquired · Grant / award795$503.47↗
Oct 15, 2026SACHS BRUCE IdirectorAcquired · Grant / award93Deferred Stock Units$512.44↗
Oct 15, 2026Garber Alan MdirectorAcquired · Grant / award29Deferred Stock Units$512.44↗
Sep 8, 2026van Grunsven JasperEVP, CP and NPPOAcquired · Grant / award8,682—↗
Aug 28, 2026Ambrose KristenSVP & Chief Accounting OfficerAcquired · Grant / award5,000—↗
Jul 21, 2026Tatsis OuraniaEVP, Chief Reg. & Quality Off.Acquired · Grant / award8,251—↗
Jul 21, 2026Sachdev AmitEVP Chief Patient & Ext Af OffAcquired · Grant / award8,251—↗
Jul 15, 2026SACHS BRUCE IdirectorAcquired · Grant / award100Deferred Stock Units$475.28↗
Jul 15, 2026Garber Alan MdirectorAcquired · Grant / award32Deferred Stock Units$475.28↗
Jul 2, 2026Tatsis OuraniaEVP, Chief Reg. & Quality Off.Disposed · Open-market sale1,500$524.99↗
Jul 2, 2026McKechnie DuncanEVP, Chief Commercial OfficerDisposed · Open-market sale1,541$519.00↗
Jul 1, 2026Liu JoyEVP and Chief Legal OfficerDisposed · Open-market sale828$502.71↗
Jun 26, 2026Bozic CarmenEVP and CMODisposed · Open-market sale596$482.50↗
Jun 18, 2026Bozic CarmenEVP and CMODisposed · Open-market sale1,020$462.17↗
Jun 15, 2026Bozic CarmenEVP and CMODisposed · Open-market sale4,062$450.00↗
Jun 5, 2026Bozic CarmenEVP and CMODisposed · Open-market sale1,745$450.00↗
Jun 1, 2026Liu JoyEVP and Chief Legal OfficerDisposed · Open-market sale828$439.91↗
May 29, 2026Bozic CarmenEVP and CMODisposed · Open-market sale1,974$450.00↗
May 15, 2026Bunnage Mark E.EVP, Chief Scientific OfficerDisposed · Open-market sale33$453.45↗
May 15, 2026Bozic CarmenEVP and CMODisposed · Open-market sale1,354$453.45↗

* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.

** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.

How much of Vertex Pharmaceuticals do institutions hold?

13F filers reported holding 12.6% of Vertex Pharmaceuticals' shares as of Sep 30, 2026, across 1,069 filers.

How many 13F filers hold Vertex Pharmaceuticals?

Vertex Pharmaceuticals was held by 1,069 13F filers as of Sep 30, 2026.

Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.